Cover Image
市場調查報告書

Cerecor Inc.的產品平台分析

Cerecor Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 285616
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
Cerecor Inc.的產品平台分析 Cerecor Inc. - Product Pipeline Review - 2014
出版日期: 2014年12月10日 內容資訊: 英文 25 Pages
簡介

Cerecor Inc.是總公司在美國的生物科技企業,進行神經疾病的治療藥研發、開發。開發中產品有NR2B性選擇性拮抗劑的CERC-301,用於減輕自殺傾向、憂鬱症。

本報告提供Cerecor Inc. 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Cerecor Inc. 的基本資料

  • Cerecor Inc. 概要
  • 主要資訊
  • 企業資料

Cerecor Inc. :R&D概要

  • 主要的治療範圍

Cerecor Inc. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Cerecor Inc. :開發中產品概況

  • 在臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段有的開發中產品
    • 前臨床階段的產品/聯合治療模式

Cerecor Inc. :藥物簡介

  • CERC-301
  • memantine hydrochloride
  • 2-MPPA
  • Small Molecules to Inhibit COMT for Cognitive Disorders

Cerecor Inc. :開發平台分析

  • 各標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Cerecor Inc. :最新的開發平台資訊

Cerecor Inc. :開發休止的計劃

Cerecor Inc. :開發中止的開發中產品

Cerecor Inc. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06624CDB

Summary

Global Markets Direct's, 'Cerecor Inc. - Product Pipeline Review - 2014', provides an overview of the Cerecor Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cerecor Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Cerecor Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Cerecor Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Cerecor Inc.'s pipeline products

Reasons to buy

  • Evaluate Cerecor Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Cerecor Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Cerecor Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Cerecor Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cerecor Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Cerecor Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Cerecor Inc. Snapshot
    • Cerecor Inc. Overview
    • Key Information
    • Key Facts
  • Cerecor Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Cerecor Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Cerecor Inc. - Pipeline Products Glance
    • Cerecor Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Cerecor Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Cerecor Inc. - Drug Profiles
    • CERC-301
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • memantine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 2-MPPA
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit COMT for Cognitive Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cerecor Inc. - Pipeline Analysis
    • Cerecor Inc. - Pipeline Products by Target
    • Cerecor Inc. - Pipeline Products by Route of Administration
    • Cerecor Inc. - Pipeline Products by Molecule Type
    • Cerecor Inc. - Pipeline Products by Mechanism of Action
  • Cerecor Inc. - Recent Pipeline Updates
  • Cerecor Inc. - Dormant Projects
  • Cerecor Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • CERC-301
  • Cerecor Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Cerecor Inc., Key Information
  • Cerecor Inc., Key Facts
  • Cerecor Inc. - Pipeline by Indication, 2014
  • Cerecor Inc. - Pipeline by Stage of Development, 2014
  • Cerecor Inc. - Monotherapy Products in Pipeline, 2014
  • Cerecor Inc. - Phase II, 2014
  • Cerecor Inc. - Preclinical, 2014
  • Cerecor Inc. - Pipeline by Target, 2014
  • Cerecor Inc. - Pipeline by Route of Administration, 2014
  • Cerecor Inc. - Pipeline by Molecule Type, 2014
  • Cerecor Inc. - Pipeline Products by Mechanism of Action, 2014
  • Cerecor Inc. - Recent Pipeline Updates, 2014
  • Cerecor Inc. - Dormant Developmental Projects,2014
  • Cerecor Inc. - Discontinued Pipeline Products, 2014

List of Figures

  • Cerecor Inc. - Pipeline by Top 10 Indication, 2014
  • Cerecor Inc. - Pipeline by Stage of Development, 2014
  • Cerecor Inc. - Monotherapy Products in Pipeline, 2014
  • Cerecor Inc. - Pipeline by Top 10 Target, 2014
  • Cerecor Inc. - Pipeline by Top 10 Route of Administration, 2014
  • Cerecor Inc. - Pipeline by Top 10 Molecule Type, 2014
  • Cerecor Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top